NMN for Sleep, Fatigue & Energy: What Human Trials Show

NMN sleep, fatigue and energy research is promising but still early. Small trials in older adults report sleep, drowsiness or fatigue-related signals; NMN does not have a consistent stimulant-like effect and the evidence is not strong enough to treat insomnia or chronic fatigue.

NMN, sleep and energy: evidence map

Claim	Human evidence	Conclusion
Better sleep quality	Small randomized older-adult trials	Preliminary positive signal
Less drowsiness	Timing RCT	Some afternoon-dosing signals
More subjective energy	Not consistently measured as a primary endpoint	Unproven
Less fatigue	Selected questionnaires / secondary outcomes	Preliminary
Keeps you awake	No consistent adverse-effect signal	Not established
Acts like caffeine	No	Different biology
Treats insomnia	No insomnia-treatment RCT	Unproven

Why NAD+ could plausibly affect sleep and fatigue

NAD metabolism intersects with mitochondrial energy production and circadian biology. That makes sleep/wake effects biologically plausible. But complex symptoms like fatigue can result from anemia, thyroid disease, sleep apnea, depression, infection, cardiopulmonary disease, medications and many other causes.

A pathway mechanism is not an appropriate substitute for evaluating persistent fatigue.

Does NMN give you immediate energy?

There is no evidence that NMN acts like caffeine. NAD-related metabolites can change relatively quickly, but controlled trials generally evaluate function and sleep over weeks.

A noticeable “boost” after the first capsule is not impossible as a personal experience, but it cannot be assumed to be a pharmacologically validated effect.

Can NMN keep you awake at night?

Insomnia has not emerged as a consistent major adverse effect in the human evidence base. Individual users may report stimulation or sleep disruption, but controlled data do not establish a predictable insomnia effect.

If sleep changes after starting any supplement, changing dose timing or stopping and reassessing is more informative than adding another supplement to counteract it.

Does NMN help chronic fatigue syndrome?

No robust randomized trial establishes NMN as a treatment for ME/CFS. Fatigue in a defined disease cannot be inferred from drowsiness or performance outcomes in healthy older adults.

Why “energy” is a difficult NMN endpoint

NAD+ is required for redox reactions that support ATP production, so the phrase “cellular energy” is biochemically reasonable. The consumer leap—from participating in energy metabolism to making a person feel energized—is much less direct.

Subjective energy depends on sleep, mood, anemia, thyroid function, fitness, calorie intake, caffeine, medications and many other factors. A supplement can change a biochemical pathway without producing a noticeable sensation.

The 2022 morning-versus-afternoon trial in context

Kim and colleagues randomized older Japanese adults to placebo or 250 mg/day NMN given in the morning or afternoon for 12 weeks. The study examined sleep, fatigue-related measures and physical performance. ^[1]

Several secondary signals favored afternoon dosing, particularly around drowsiness and lower-body function. Other sleep and fatigue measures did not show a uniform NMN advantage. That mixed pattern is why the study should not be summarized as “NMN fixes sleep” or “take it at 2 p.m.”

The 2024 older-adult sleep study

Morifuji and colleagues reported increased blood NAD levels together with maintained walking speed and improved Pittsburgh Sleep Quality Index scores in an older-adult randomized trial. ^[2]

The study is supportive because it provides a second controlled human dataset involving sleep-related outcomes. But sleep was part of a broader trial, and the primary physical-performance endpoint was not a dramatic across-the-board positive. A dedicated insomnia trial would use sleep as the central prespecified outcome and ideally include objective actigraphy or polysomnography.

Why studies can disagree on sleep

Sleep questionnaires measure different constructs. Global sleep quality, daytime drowsiness, fatigue, sleep latency and total sleep time are not interchangeable. Small trials can also differ by baseline sleep problems, time of dosing, age and chance.

A review of early NMN trials has therefore described sleep results more cautiously than consumer articles that quote only the most positive subscale. This is a classic example of why endpoint-level reading matters.

Does NMN interact with the circadian clock?

NAD biology is linked to circadian signaling, but human trials have not established a clinically useful NMN timing effect. NAD metabolism and circadian signaling are biologically connected, including through NAD-dependent enzymes and daily metabolic rhythms. That provides a plausible reason timing could matter. It does not tell us the clinically optimal hour.

The human evidence is still too small to prescribe NMN as chronotherapy or to claim that taking it at the 'wrong' time disrupts circadian biology.

What happens if NMN feels stimulating?

Individual effects can differ from trial averages. If someone consistently notices difficulty falling asleep after later dosing, moving the dose earlier is a reasonable self-observation strategy. That practical adjustment should not be confused with proof that NMN is a stimulant.

It is also worth separating NMN from the rest of the stack. Coffee, pre-workouts, stimulating adaptogens and sleep loss are more established explanations for acute alertness than NMN.

Fatigue is a symptom, not a diagnosis

Persistent fatigue can reflect sleep apnea, iron deficiency, anemia, hypothyroidism, depression, cardiopulmonary disease, infection, under-fueling, medication effects and many other conditions. A longevity supplement should not become a diagnostic shortcut.

There is no robust randomized evidence that NMN treats ME/CFS, post-viral fatigue syndromes or unexplained chronic fatigue.

What about exercise-related fatigue?

Some physical-function and endurance studies report positive NMN signals, but those are distinct from everyday subjective energy. The amateur-runner trial measured exercise physiology, while older-adult trials assessed gait or functional tests. ^[3]

For the performance evidence, see NMN for exercise and muscle.

How strong is the overall evidence?

Outcome	Evidence strength	Why
Raises blood NAD-related markers	Relatively strong	Repeated human studies
Improves sleep quality	Preliminary	Small trials; often secondary outcomes
Reduces daytime drowsiness	Preliminary	Timing-specific signals
Treats insomnia	Unproven	No definitive insomnia trial
Produces immediate energy	Unproven	Not a consistent primary endpoint
Treats chronic fatigue disorders	Unproven	No condition-specific efficacy evidence

Human sleep and fatigue studies compared

Study	Population	Main sleep/energy finding
Kim 2022	Older adults	Timing-dependent drowsiness and physical-function signals
Morifuji 2024	Older adults	Walking and sleep-quality signals
Longer-term observational/intervention work	Middle-aged/older adults	Selected sleep/metabolic measures, not a validated insomnia treatment

Kim's randomized timing study is important because it contradicts the simplistic claim that NMN must always be taken in the morning. ^[4] Morifuji reported additional sleep-quality signals in older adults. ^[5]

2026 REM-sleep mechanism: what the mouse study adds

A 2026 iScience study identified a specific NMN-responsive sleep circuit in aged mice. NMN restored firing of REM-active bursting slow-oscillation neurons in the supramammillary nucleus toward younger levels and increased REM-related activity in the model. ^[6]

This gives the sleep hypothesis a more specific mechanism than “NAD+ supports energy.” It still does not establish that oral NMN treats insomnia or improves human REM sleep. The human sleep evidence remains based on small trials with subjective or actigraphy-related outcomes, while this new paper is preclinical neurobiology.

What “more energy” can mean

Energy can refer to cellular redox metabolism, exercise capacity, daytime alertness, fatigue severity or simply subjective motivation. These are not interchangeable outcomes. NMN clearly affects NAD-related biochemistry; it does not reliably behave like caffeine or another acute stimulant.

September 2026 synthesis: sleep and perceived fatigue remain unproven

The newest network meta-analysis separated perceived fatigue, exercise performance, cognition, quality of life and sleep rather than treating them as one “energy” outcome. Across 27 NAD+ precursor studies, no precursor significantly improved perceived fatigue, and no meaningful sleep-quality improvement was established. NMN did not show a cognitive-performance benefit in the network. ^[7]

That strengthens an important distinction on this page: small NMN trials can show sleep, drowsiness or daytime-function signals without establishing NMN as a treatment for insomnia, chronic fatigue or cognitive “brain fog.”

When fatigue should not be self-treated with NMN

Persistent fatigue can reflect sleep apnea, anemia, thyroid disease, depression, medication effects, infection, cardiopulmonary disease or other conditions. A supplement experiment should not delay evaluation when fatigue is new, severe or accompanied by weight loss, breathlessness, chest symptoms or other concerning features.

Related NMN guides

• NMN and exercise performance
• NMN timing
• NMN benefits
• NMN human trials

Bottom line

Sleep and fatigue are among the more intriguing secondary NMN outcomes because multiple small human studies point in the same general direction. The evidence is not yet strong enough to call NMN a sleep aid or fatigue treatment.